HIV-RNA and total HIV-DNA loads in plasma and semen in patients with detectable HIV-RNA or HIV-DNA in semen at W48
Subject ID . | Regimen type . | Semen HIV-1- RNA (log10 copies/mL) . | Semen total HIV-1-DNA (log10 copies/106 cells) . | Plasma HIV-1- RNA (log10 copies/mL) . | Blood total HIV-1-DNA (log10 copies/106 PBMCs) . | Observations . | ||||
---|---|---|---|---|---|---|---|---|---|---|
W0 . | W48 . | W0 . | W48 . | W0 . | W48 . | W0 . | W48 . | |||
#1 | DTG | (W2) 2.75 | 1.79 | (W2) 2.84 | <3.20 | 4.16 | <0.52 | 3.22 | 2.76 | self-reported correct treatment adherence until W24; no response for W48 |
#2 | DTG | 6.48 | 2.94 | NA | NA | 6.39 | 1.69 | 3.72 | 2.83 | self-reported adherence failures at W4 and W48 |
#3 | DRV | NA | 2.40 | NA | 1.88 | 6.45 | detected <0.52 | 4.21 | 2.74 | self-reported adherence failures at W4 and W24 |
#4 | DRV | 6.04 | 1.57 | 1.59 | <1.50 | 5.74 | 1.00 | 3.96 | 2.80 | self-reported adherence failures at W8 and W24 |
#5 | DRV | NA | 3.28 | NA | <2.11 | 6.89 | 2.20 | 4.26 | 3.56 | self-reported correct treatment adherence until W12; no responses for W24 and W48; STI W24, W36 and W48 |
#6 | DRV | NA | 1.50 | NA | <1.99 | 5.85 | 1.75 | 4.05 | 3.15 | self-reported adherence failures at W8, W24, W36 and W48; STI W24 |
#7 | DRV | (W2) <1.71 | <2.13 | (W2) <1.71 | 2.36 | 4.94 | 0.48 | 3.18 | 2.39 | self-reported adherence failures at W4, W8, W36 and W48; STI W36 |
#8 | DTG | NA | <2.01 | NA | 2.57 | 5.31 | 1.18 | 3.76 | 2.76 | self-reported adherence failures at each timepoint |
Subject ID . | Regimen type . | Semen HIV-1- RNA (log10 copies/mL) . | Semen total HIV-1-DNA (log10 copies/106 cells) . | Plasma HIV-1- RNA (log10 copies/mL) . | Blood total HIV-1-DNA (log10 copies/106 PBMCs) . | Observations . | ||||
---|---|---|---|---|---|---|---|---|---|---|
W0 . | W48 . | W0 . | W48 . | W0 . | W48 . | W0 . | W48 . | |||
#1 | DTG | (W2) 2.75 | 1.79 | (W2) 2.84 | <3.20 | 4.16 | <0.52 | 3.22 | 2.76 | self-reported correct treatment adherence until W24; no response for W48 |
#2 | DTG | 6.48 | 2.94 | NA | NA | 6.39 | 1.69 | 3.72 | 2.83 | self-reported adherence failures at W4 and W48 |
#3 | DRV | NA | 2.40 | NA | 1.88 | 6.45 | detected <0.52 | 4.21 | 2.74 | self-reported adherence failures at W4 and W24 |
#4 | DRV | 6.04 | 1.57 | 1.59 | <1.50 | 5.74 | 1.00 | 3.96 | 2.80 | self-reported adherence failures at W8 and W24 |
#5 | DRV | NA | 3.28 | NA | <2.11 | 6.89 | 2.20 | 4.26 | 3.56 | self-reported correct treatment adherence until W12; no responses for W24 and W48; STI W24, W36 and W48 |
#6 | DRV | NA | 1.50 | NA | <1.99 | 5.85 | 1.75 | 4.05 | 3.15 | self-reported adherence failures at W8, W24, W36 and W48; STI W24 |
#7 | DRV | (W2) <1.71 | <2.13 | (W2) <1.71 | 2.36 | 4.94 | 0.48 | 3.18 | 2.39 | self-reported adherence failures at W4, W8, W36 and W48; STI W36 |
#8 | DTG | NA | <2.01 | NA | 2.57 | 5.31 | 1.18 | 3.76 | 2.76 | self-reported adherence failures at each timepoint |
NA, not available; DTG, dolutegravir-based regimen; DRV, darunavir-based regimen; STI, sexually transmitted infection.
HIV-RNA and total HIV-DNA loads in plasma and semen in patients with detectable HIV-RNA or HIV-DNA in semen at W48
Subject ID . | Regimen type . | Semen HIV-1- RNA (log10 copies/mL) . | Semen total HIV-1-DNA (log10 copies/106 cells) . | Plasma HIV-1- RNA (log10 copies/mL) . | Blood total HIV-1-DNA (log10 copies/106 PBMCs) . | Observations . | ||||
---|---|---|---|---|---|---|---|---|---|---|
W0 . | W48 . | W0 . | W48 . | W0 . | W48 . | W0 . | W48 . | |||
#1 | DTG | (W2) 2.75 | 1.79 | (W2) 2.84 | <3.20 | 4.16 | <0.52 | 3.22 | 2.76 | self-reported correct treatment adherence until W24; no response for W48 |
#2 | DTG | 6.48 | 2.94 | NA | NA | 6.39 | 1.69 | 3.72 | 2.83 | self-reported adherence failures at W4 and W48 |
#3 | DRV | NA | 2.40 | NA | 1.88 | 6.45 | detected <0.52 | 4.21 | 2.74 | self-reported adherence failures at W4 and W24 |
#4 | DRV | 6.04 | 1.57 | 1.59 | <1.50 | 5.74 | 1.00 | 3.96 | 2.80 | self-reported adherence failures at W8 and W24 |
#5 | DRV | NA | 3.28 | NA | <2.11 | 6.89 | 2.20 | 4.26 | 3.56 | self-reported correct treatment adherence until W12; no responses for W24 and W48; STI W24, W36 and W48 |
#6 | DRV | NA | 1.50 | NA | <1.99 | 5.85 | 1.75 | 4.05 | 3.15 | self-reported adherence failures at W8, W24, W36 and W48; STI W24 |
#7 | DRV | (W2) <1.71 | <2.13 | (W2) <1.71 | 2.36 | 4.94 | 0.48 | 3.18 | 2.39 | self-reported adherence failures at W4, W8, W36 and W48; STI W36 |
#8 | DTG | NA | <2.01 | NA | 2.57 | 5.31 | 1.18 | 3.76 | 2.76 | self-reported adherence failures at each timepoint |
Subject ID . | Regimen type . | Semen HIV-1- RNA (log10 copies/mL) . | Semen total HIV-1-DNA (log10 copies/106 cells) . | Plasma HIV-1- RNA (log10 copies/mL) . | Blood total HIV-1-DNA (log10 copies/106 PBMCs) . | Observations . | ||||
---|---|---|---|---|---|---|---|---|---|---|
W0 . | W48 . | W0 . | W48 . | W0 . | W48 . | W0 . | W48 . | |||
#1 | DTG | (W2) 2.75 | 1.79 | (W2) 2.84 | <3.20 | 4.16 | <0.52 | 3.22 | 2.76 | self-reported correct treatment adherence until W24; no response for W48 |
#2 | DTG | 6.48 | 2.94 | NA | NA | 6.39 | 1.69 | 3.72 | 2.83 | self-reported adherence failures at W4 and W48 |
#3 | DRV | NA | 2.40 | NA | 1.88 | 6.45 | detected <0.52 | 4.21 | 2.74 | self-reported adherence failures at W4 and W24 |
#4 | DRV | 6.04 | 1.57 | 1.59 | <1.50 | 5.74 | 1.00 | 3.96 | 2.80 | self-reported adherence failures at W8 and W24 |
#5 | DRV | NA | 3.28 | NA | <2.11 | 6.89 | 2.20 | 4.26 | 3.56 | self-reported correct treatment adherence until W12; no responses for W24 and W48; STI W24, W36 and W48 |
#6 | DRV | NA | 1.50 | NA | <1.99 | 5.85 | 1.75 | 4.05 | 3.15 | self-reported adherence failures at W8, W24, W36 and W48; STI W24 |
#7 | DRV | (W2) <1.71 | <2.13 | (W2) <1.71 | 2.36 | 4.94 | 0.48 | 3.18 | 2.39 | self-reported adherence failures at W4, W8, W36 and W48; STI W36 |
#8 | DTG | NA | <2.01 | NA | 2.57 | 5.31 | 1.18 | 3.76 | 2.76 | self-reported adherence failures at each timepoint |
NA, not available; DTG, dolutegravir-based regimen; DRV, darunavir-based regimen; STI, sexually transmitted infection.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.